Research presented at IDWeek has discovered that users of the social networking app, Grindr, took more risks and had more partners but were more likely to use, or be open to using, PrEP compared with those who didn’t use the app.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
Find out more about the headlines from the 10th International AIDS Society Conference on HIV Science (IAS 2019) in our round-up of conference news.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
A report analyzing the prevalence and incidence of chlamydia, gonorrhea, trichomoniasis and syphilis for 2016 has reported that rates of these four curable sexually transmitted infections remain high, estimating 376.4 million cases in 2016.
Early antiretroviral treatment in people with HIV infection could allow the generation of more functional and persistent CD8 T cell responses. The results, which suggest a long-term immune memory, could have implications for HIV vaccine development.
Healthcare practitioners have split opinions on whether primary care doctors or other providers should take the lead on prescribing PrEP for HIV prevention, according to new research.
New research describes the use of small-molecule CD4 mimetic compounds that force HIV to undergo conformational changes, exposing normally hidden parts of the envelope and potential new targets.
A second individual has achieved sustained remission from HIV-1 after ceasing antiretroviral treatment, according to researchers from University College London. Following a hematopoietic stem cell transplant and chemotherapy the patient has had undetectable viral loads for 18 months.
New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
